Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32748
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiu, Mengjie-
dc.contributor.authorLi, Qingyang-
dc.contributor.authorDelaine, Carlie-
dc.contributor.authorWu, Hongkang-
dc.contributor.authorArsenakis, Yanni-
dc.contributor.authorWhite, Barbara F-
dc.contributor.authorForbes, Briony E-
dc.contributor.authorChandrashekar, Chaitra-
dc.contributor.authorHossain, Mohammed Akhter-
dc.date2023-
dc.date.accessioned2023-04-26T05:24:19Z-
dc.date.available2023-04-26T05:24:19Z-
dc.date.issued2023-04-18-
dc.identifier.citationACS Omega 2023; 8(15)en_US
dc.identifier.issn2470-1343-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32748-
dc.description.abstractCommercially available insulins are manufactured by recombinant methods for the treatment of diabetes. Long-acting insulin drugs (e.g., detemir and degludec) are obtained by fatty acid conjugation at LysB29 ε-amine of insulin via acid-amide coupling. There are three amine groups in insulin, and they all react with fatty acids in alkaline conditions. Due to the lack of selectivity, such conjugation reactions produce non-desired byproducts. We designed and chemically synthesized a novel thiol-insulin scaffold (CysB29-insulin II), by replacing the LysB29 residue in insulin with the CysB29 residue. Then, we conjugated a fatty acid moiety (palmitic acid, C16) to CysB29-insulin II by a highly efficient and selective thiol-maleimide conjugation reaction. We obtained the target peptide (palmitoyl-insulin) rapidly within 5 min without significant byproducts. The palmitoyl-insulin is shown to be structurally similar to insulin and biologically active both in vitro and in vivo. Importantly, unlike native insulin, palmitoyl-insulin is slow and long-acting.en_US
dc.language.isoeng-
dc.titleTotal Chemical Synthesis of Palmitoyl-Conjugated Insulin.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleACS Omegaen_US
dc.identifier.affiliationMonash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia.;The Florey Institute of Neuroscience and Mental Health, Parkville 3052, Australia.en_US
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen_US
dc.identifier.affiliationDiscipline of Medical Biochemistry, College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia.en_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationDiscipline of Medical Biochemistry, College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia.en_US
dc.identifier.affiliationSchool of Chemistry, and Department of Biochemistry and Pharmacology, The University of Melbourne, Victoria 3010, Australia.en_US
dc.identifier.doi10.1021/acsomega.2c07918en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-4360-9927en_US
dc.identifier.orcid0000-0002-0288-5952en_US
dc.identifier.orcid0000-0002-9961-0006en_US
dc.identifier.pubmedid37091377-
dc.description.volume8-
dc.description.issue15-
dc.description.startpage13715-
dc.description.endpage13720-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 10, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.